Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics (LON:IDHC) and Diaceutics (LON:DXRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Does the media favor IDHC or DXRX?

In the previous week, Integrated Diagnostics and Integrated Diagnostics both had 1 articles in the media. Integrated Diagnostics' average media sentiment score of 0.67 beat Diaceutics' score of 0.00 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integrated Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Diaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings & valuation, IDHC or DXRX?

Integrated Diagnostics has higher revenue and earnings than Diaceutics. Diaceutics is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated Diagnostics	£23.29T	0.00	£4.01T	£0.03	11.78
Diaceutics	£26.08M	3.98	-£2.84M	-£3.37	-36.51

Is IDHC or DXRX more profitable?

Integrated Diagnostics has a net margin of 17.21% compared to Diaceutics' net margin of -10.90%. Integrated Diagnostics' return on equity of 30.45% beat Diaceutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integrated Diagnostics	17.21%	30.45%	9.69%
Diaceutics	-10.90%	-7.15%	-6.06%

Do analysts recommend IDHC or DXRX?

Diaceutics has a consensus price target of GBX 160, indicating a potential upside of 29.98%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Integrated Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, IDHC or DXRX?

Integrated Diagnostics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Does the MarketBeat Community believe in IDHC or DXRX?

Integrated Diagnostics received 41 more outperform votes than Diaceutics when rated by MarketBeat users. However, 88.24% of users gave Diaceutics an outperform vote while only 65.12% of users gave Integrated Diagnostics an outperform vote.

Company	Underperform	Outperform
Integrated Diagnostics	Outperform Votes 56 65.12%	Underperform Votes 30 34.88%
Diaceutics	Outperform Votes 15 88.24%	Underperform Votes 2 11.76%

Do insiders & institutionals have more ownership in IDHC or DXRX?

43.0% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 52.4% of Diaceutics shares are held by institutional investors. 34.0% of Integrated Diagnostics shares are held by insiders. Comparatively, 34.3% of Diaceutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Integrated Diagnostics beats Diaceutics on 10 of the 17 factors compared between the two stocks.